New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Check below for free stories on CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
August 29, 2014
16:01 EDTPBROptions Update; August 29, 2014
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
16:00 EDTPBROptions Update; August 28, 2014
Subscribe for More Information
11:13 EDTJCP, PBRStocks with call strike movement; JCP PBR
J.C. Penney (JCP) February 12 call option implied volatility increased 4% to 43, Petrobras (PBR) December 23 call option implied volatility increased 4% to 45 according to IVolatility.
09:57 EDTJCPOn The Fly: Analyst Downgrade Summary
Brown Forman (BFA, BFB, BF.A, BF.B) downgraded to Hold from Buy at Deutsche Bank... GT Advanced (GTAT) downgraded to Underperform from Market Perform at Raymond James... Genuine Parts (GPC) downgraded to Neutral from Buy at SunTrust... InterMune (ITMN) downgraded to Neutral from Buy at UBS... Tesco (TSCDY) downgraded to Hold from Buy at Deutsche Bank... Visa (V) downgraded to Market Perform from Outperform at Raymond James... Williams-Sonoma (WSM) downgraded to Equal Weight from Overweight at Morgan Stanley... Bob Evans (BOBE) downgraded to Underweight from Equal Weight at Stephens... lululemon (LULU) downgraded to Neutral from Buy at DA Davidson... J.C. Penney (JCP) downgraded to Neutral from Buy at BTIG.
08:57 EDTGRMNGarmin feedback indicates slower Vivofit sales, says Morgan Stanley
Subscribe for More Information
08:05 EDTJCPJ.C. Penney downgraded at BTIG
Subscribe for More Information
07:43 EDTJCPJ.C. Penney downgraded to Neutral from Buy at BTIG
Subscribe for More Information
August 27, 2014
16:00 EDTPBROptions Update; August 27, 2014
iPath S&P 500 VIX Short-Term Futures up 26c to 27.89 Option volume leaders: AAPLTWTR TSLA PBR RSH GILD MCD AMZN WFM according to Track Data.
11:53 EDTPBRPetrobras hits a new 52-week high, levels to watch
Subscribe for More Information
11:31 EDTPBRStocks with call strike movement; GATE PBR
Subscribe for More Information
09:53 EDTGRMN, BMYOn The Fly: Analyst Initiation Summary
Bristol-Myers (BMY) initiated with a Hold at Deutsche Bank... ASML (ASML) initiated with a Hold at Stifel... Akamai (AKAM) initiated with an Outperform at RW Baird... Concur (CNQR) initiated with a Neutral at DA Davidson... CyrusOne (CONE) initiated with a Neutral at Citigroup... Eli Lilly (LLY) initiated with a Buy at Deutsche Bank... Garmin (GRMN) initiated with a Neutral at RW Baird... Merck (MRK) initiated with a Hold at Deutsche Bank... NetSuite (N) initiated with a Buy at DA Davidson... Oracle (ORCL) initiated with a Neutral at DA Davidson... Oxford Industries (OXM) initiated with a Buy at Wunderlich... Pfizer (PFE) initiated with a Buy at Deutsche Bank... ServiceNow (NOW) initiated with a Buy at DA Davidson... Workday (WDAY) initiated with a Neutral at DA Davidson... MannKind (MNKD) initiated with a Buy at Jefferies... STMicroelectronics (STM) initiated with an Underperform at Credit Suisse... Kirkland's (KIRK) initiated with an Outperform at Barrington.
09:08 EDTNKTRNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
07:45 EDTJCPJ.C. Penney volatility at 27-month low
Subscribe for More Information
06:42 EDTBMYBristol-Myers initiated with a Hold at Deutsche Bank
Target $52.
05:44 EDTBMYBristol-Myers Daklinza approved by EC
Bristol-Myers announced that the European Commission, or EC, has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus, or HCV, infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the European Union and will be available for use in combination with other medicinal products, providing a shorter treatment duration compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. The approval allows for the marketing of Daklinza in all 28 Member States of the EU. The marketing authorization for Daklinza follows an accelerated assessment by the Committee for Medicinal Products for Human Use, a designation that is granted to new medicines of major public health interest.
August 26, 2014
16:21 EDTGRMNGarmin initiated with a Neutral at RW Baird
Subscribe for More Information
12:10 EDTPBRStocks with call strike movement; SUNE PBR
Subscribe for More Information
09:35 EDTPBRActive equity options trading on open
Subscribe for More Information
August 25, 2014
16:00 EDTPBROptions Update; August 25, 2014
Subscribe for More Information
12:16 EDTJCPJ.C. Penney rises, levels to watch
The stock is holding above what was strong resistance at the $10 area. JPMorgan earlier recommended the shares as a long idea, and the stock is up over 4.6% on greater than average daily volume to $10.65. At that price, next resistance is at $11.22. Support is at $10.42.
10:16 EDTJCPJ.C. Penney rises after analyst predicts more store closures coming
Subscribe for More Information
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:37 EDTJCPJ.C. Penney recommneded as a Long Trade Idea at JPMorgan
Subscribe for More Information
07:23 EDTSTRAGovernment not looking to push other colleges out of business, says Wells Fargo
In the wake of Corinthian Colleges' (COCO) dissolution due to actions taken by the Department of Education, Wells Fargo thinks the government did not intend for this scenario to unfold. After speaking with unnamed "knowledgeable sources" about the issue, the firm does not expect the department to take similar actions in the future because doing so would create too much of a workload for the department, Wells believes. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
15:41 EDTGRMNGarmin, JVC Kenwood to co-develop carmaker navigation systems, Nikkei reports
Subscribe for More Information
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
16:57 EDTVNOVornado JV sells Georgetown Park for $272.5M
Vornado Realty Trust announced that a joint venture owned equally by Vornado’s real estate fund and its joint venture partner, a real estate fund managed by Angelo, Gordon & Co., have sold Georgetown Park for $272.5M. Vornado owns 25% of Vornado Capital Partners. Georgetown Park is a prominent 305,000 square foot multi-level retail property located at M Street and Wisconsin Avenue in Georgetown. Vornado was responsible for developing and leasing the property, which was completely renovated and transformed, reconfiguring its floor plates to accommodate large format retail tenants with modern tenant demands.
15:37 EDTNKTRNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
10:35 EDTJCPSears falls after reporting Q2 loss that more than doubled analyst projections
Subscribe for More Information
10:22 EDTJCPOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD VHC ACHN JCP WB JD YPF
10:13 EDTPBRStocks with call strike movement; PBR FIVE
Subscribe for More Information
06:01 EDTPBRPetrobras implied volatility of 45 at upper end of index mean range
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
16:01 EDTPBROptions Update; August 20, 2014
Subscribe for More Information
11:50 EDTPBRStocks with call strike movement; PBR BBRY
Subscribe for More Information
11:42 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:39 EDTCATCaterpillar data may be negative for shares in short-term, says Wells Fargo
Subscribe for More Information
10:35 EDTCATCaterpillar reported world Machines sales down 9%
Subscribe for More Information
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
07:01 EDTGRMNGarmin introduces first Android-based fleet navigators
Subscribe for More Information
05:51 EDTJCPStocks with implied volatility movement; JCP VHC
Subscribe for More Information
August 19, 2014
16:00 EDTPBROptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
11:14 EDTPBRStocks with call strike movement; PBR UAL
Subscribe for More Information
10:42 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
08:10 EDTPBRFMC Technologies awarded order by Petrobras
Subscribe for More Information
06:14 EDTPBRPetrobras implied volatility of 45 at upper end of index mean range
Subscribe for More Information
August 18, 2014
11:57 EDTJCPStocks with call strike movement; JCP GPRO
J.C. Penney (JCP) November 11 call option implied volatility decreased 4% to 43, GoPro (GPRO) January 48 call option implied volatility decreased 8% to 45 according to IVolatility.
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
07:57 EDTBMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:05 EDTPBRPetrobras implied volatility of 49 at upper end of index mean range
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use